Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

https://www.soho2019.com/

 

Chronic Lymphocytic Leukemia
13:15

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Shifting Standard of Care for Frontline Therapy of CLL: Which Patients Benefit the Most from FCR, Ibrutinib Leads to Impressive PFS,What's the Ideal BCL2i Combo and Ideal Rx Duration?

FEATURING Nitin Jain
  • 421 views
  • October 18, 2019
  • 1
11:37

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

CLL State of the Art Update: Ibrutinib Prolongs PFS Compared to CIT, Combinations Achieve uMRD, Venetoclax Obinutuzumab is Highly Effective, & Next Generation BTKi's Are Better Tolerated

FEATURING Jennifer Brown
  • 324 views
  • October 18, 2019
  • 1
15:20

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Discussion on the Next Generation Small Molecules in CLL: 2nd Generation Covalent BTKi, Reversible BTKi, Novel PI3Ki, and Other Targets of Interest

FEATURING Jennifer Woyach
  • 136 views
  • October 18, 2019
05:46

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

62 y/o Male Diagnosed With CLL, Treated w/Mono Retuximab, Differential Diagnosis Incl. Mycobacterial Infection (BCGosis)

FEATURING Alessandra Ferrajoli
  • 19 views
  • October 18, 2019
04:13

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

72 y/o Female w/Relapsed Rai Stage IV CLL Treated w/Ibrutinib and Rituximab, Elevated WBC Due to Redistribution Leukocytosis

FEATURING Alessandra Ferrajoli
  • 16 views
  • November 12, 2019
06:07

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

63 y/o Male w/Untreated CLL Rai I, Acute Hepatitis and Fever Work-Up Due to Viral Hepatitis

FEATURING Alessandra Ferrajoli
  • 13 views
  • November 12, 2019
13:11

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

CAR-T Cell Therapy in Chronic Lymphocytic Leukemia (CLL): Manageable Toxicity and Promising Clinical Activity of Liso-Cel

FEATURING Tanya Siddiqi
  • 58 views
  • October 18, 2019
16:05

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Reassessing Prognostic Markers (IGHV, TP53, CD49d, and B2M) in the Era of Targeted Therapy: How Have Prognostic Factors Changed with Novel Therapies in CLL?

FEATURING Adrian Wiestner
  • 216 views
  • October 18, 2019
06:23

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

BTKi Acalabrutinib with anti-CD20 Obinutuzumab in Treatment-Naive and R/R CLL After 3-Year FollowUp Yielded High Responsive Durable Rates

FEATURING Jennifer Woyach
  • 452 views
  • October 18, 2019
07:41

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

CLL and Therapy Related Myeloid Neoplasia in Chemoimmunotherapy Era: Norway Data

FEATURING Andrea Lenartova
  • 16 views
  • October 18, 2019